Pfiz­er boosts its gene ther­a­py work, bags up­start Bam­boo in $645M buy­out deal

Bam­boo Ther­a­peu­tics and its nascent gene ther­a­py pipeline is be­ing bought out by Pfiz­er, just five months af­ter the biotech raised close to $50 mil­lion. The phar­ma gi­ant, al­ready a mi­nor­i­ty in­vestor in Bam­boo, is pay­ing $150 mil­lion up­front for the rest of the eq­ui­ty as it sets its sights on be­com­ing a leader in gene ther­a­py de­vel­op­ment. And there’s an­oth­er $495 mil­lion in mile­stones on the ta­ble for Bam­boo’s in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.